These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi. Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y. Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685 [Abstract] [Full Text] [Related]
3. Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans. Wahid R, Fresnay S, Levine MM, Sztein MB. Mucosal Immunol; 2015 Nov; 8(6):1349-59. PubMed ID: 25872480 [Abstract] [Full Text] [Related]
5. Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate. Xiong K, Chen Z, Zhu C, Li J, Hu X, Rao X, Cong Y. Int J Med Microbiol; 2015 Sep; 305(6):563-71. PubMed ID: 26239100 [Abstract] [Full Text] [Related]
15. Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever. Howlader DR, Koley H, Sinha R, Maiti S, Bhaumik U, Mukherjee P, Dutta S. PLoS One; 2018 Sep; 13(9):e0203631. PubMed ID: 30216367 [Abstract] [Full Text] [Related]
19. Status of paratyphoid fever vaccine research and development. Martin LB, Simon R, MacLennan CA, Tennant SM, Sahastrabuddhe S, Khan MI. Vaccine; 2016 Jun 03; 34(26):2900-2902. PubMed ID: 27083427 [Abstract] [Full Text] [Related]